J P Fermand
Overview
Explore the profile of J P Fermand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
654
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roupie A, Battistella M, Talbot A, Jachiet M, Bouaziz J, Vignon-Pennamen M, et al.
J Eur Acad Dermatol Venereol
. 2018 Sep;
33(3):e104-e106.
PMID: 30267590
No abstract available.
2.
Baron M, Lozeron P, Harel S, Bengoufa D, Vignon M, Asli B, et al.
J Neurol
. 2017 May;
264(6):1132-1135.
PMID: 28484839
Monoclonal IgM anti-myelin-associated glycoprotein (MAG) antibody-related peripheral neuropathy (anti-MAG neuropathy) is predominantly a demyelinating sensory neuropathy with ataxia and distal paresthesia. The clinical course of anti-MAG neuropathy is usually slowly...
3.
Vignon M, Placais L, Malphettes M, Bouaziz J, Asli B, Bedossa P, et al.
J Eur Acad Dermatol Venereol
. 2017 Mar;
31(9):e403-e405.
PMID: 28295661
No abstract available.
4.
Vignon M, Javaugue V, Alexander M, El-Karoui K, Karras A, Roos-Weil D, et al.
Leukemia
. 2016 Jul;
31(1):123-129.
PMID: 27435002
We retrospectively reviewed 49 patients with light chain (LC) Fanconi syndrome (FS). Patients presented with chronic kidney disease (median estimated glomerular filtration rate (eGFR) of 33 ml/min/1.73 m) and tubular...
5.
Fouquet G, Pegourie B, Macro M, Petillon M, Karlin L, Caillot D, et al.
Ann Oncol
. 2016 Jan;
27(5):902-7.
PMID: 26787238
Background: The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM). We observed that 40% of patients had...
6.
Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien M, et al.
Leukemia
. 2013 Apr;
27(11):2242-4.
PMID: 23558525
No abstract available.
7.
Penot A, Abraham J, Debarri H, Desport E, Aguilar C, Lavergne D, et al.
Amyloid
. 2011 Aug;
18 Suppl 1:145-7.
PMID: 21838466
No abstract available.
8.
Armoiry X, Fagnani F, Benboubker L, Facon T, Fermand J, Hulin C, et al.
J Clin Pharm Ther
. 2011 Jan;
36(1):19-26.
PMID: 21198717
What Is Known And Background: For relapsed or refractory multiple myeloma (RRMM), a series of novel agents (thalidomide, bortezomib and lenalidomide) has emerged during the latest decade, but their use...
9.
Karlin L, Arnulf B, Chevret S, Ades L, Robin M, De Latour R, et al.
Bone Marrow Transplant
. 2010 Apr;
46(2):250-6.
PMID: 20400980
We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous-allogeneic tandem approach. Tandem...
10.
Chandesris M, Soulier J, Labaume S, Crinquette A, Repellini L, Chemin K, et al.
Br J Haematol
. 2007 Jan;
136(4):609-14.
PMID: 17223917
The t(4;14)(p16;q32) translocation, found in 15% of multiple myeloma (MM) cases, indicates a poor prognosis. Plasma cells (PC) with t(4;14) ectopically express the fibroblast growth factor receptor 3 (FGFR3) tyrosine...